University of Patras
Αντιμετώπιση κρίσης ουρικής αρθρίτιδας σε νοσηλευόμενους ασθενείς
Abstract
dc:descriptionThe management of acute gout in the hospital setting may be challenging since most patients are elderly with multiple unstable comorbidities. However, there are no prospective clinical trials for hospitalized patients with gout to guide optimal management. Evidence indicates that steroids or adrenocorticotropic hormone (ACTH) may be similarly effective and safe therapeutic options for these patients. This study aimed at directly comparing the efficacy and safety of ACTH vs betamethasone for the treatment of gout in hospitalized patients. This is the first prospective clinical trial for hospitalized patients with gout. A randomized, open label study was designed to assess the efficacy and safety of a single intramuscular injection of either ACTH or betamethasone in hospitalized patients with acute gout. Primary efficacy endpoints were the change in intensity of pain as recorded using a Visual Analogue Scale (VAS) at baseline compared to 24 h(ΔVAS24h), and 48 h (ΔVAS48h). Moreover, the effects of both treatments on the hypothalamic–pituitary–adrenal (HPA) axis, glucose and lipid homeostasis, bone metabolism, electrolytes and renal function were also assessed. A total of 38 patients were recruited. Both treatments were highly effective. The mean ± SE ΔVAS24h andΔVAS48h for ACTH was 4.48 ± 0.29 and 5.58± 0.26, respectively. The mean± SEΔVAS24h and ΔVAS48h for betamethasone was 4.67 ± 0.32 and 5.67± 0.28,respectively. Direct comparison between the two groups at 24 h and 48 h did not show statistically significant differences. Both treatments were well tolerated and safe. The effects on all metabolic parameters were mostly minimal and transient for both treatments. However, ACTH may affect less the HPA axis and bone metabolism compared to betamethasone. Overall, ACTH and betamethasone are both effective and safe for the management of acute gout in hospitalized patients, but ACTH may associate with less disturbance of the HPA axis and bone metabolism. Therefore, these data support the use of both drugs as first line treatments for hospitalized patients with gout.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kordas, Panagiotis
- Κόρδας, Παναγιώτης
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55875